Last mentioned: Mar 22, 2026
Litigation Filed
Pomerantz LLP announces the filing of a class action lawsuit against Nektar.
Partnership Termination
BMS and Nektar officially end their global clinical development collaboration.
Phase 3 Failure
Lead melanoma trial fails to meet primary endpoints, causing stock to plummet.
BMS Partnership
Nektar signs a $3.6B deal with Bristol Myers Squibb for bempegaldesleukin.
Pomerantz LLP has initiated class action litigation against Nektar Therapeutics, alleging the company made false or misleading statements regarding its clinical programs and business prospects. The lawsuit seeks to recover damages for investors following significant stock volatility linked to the company's oncology pipeline performance.
This page surfaces every story mentioning Enphase Energy across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Enphase Energy was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |